Skip to main content Skip to navigation

ADAPT SEPSIS

Hospital ward

Latest news

Recruitment Closed 5th June 2024!

Thank you to all of our Investigator Sites for their tremendous efforts and dedication in reaching the recruitment target for Adapt-Sepsis. This significant milestone would not have been possible without your unwavering commitment, hard work, and collaboration. As a result of the trial has now stopped recruiting and the database has been updated to stop any further randomisations, therefore you will not be able to access this page.

ADAPT Protocol Published

By the Journal of the Intensive Care Society.

RISC Sepsis Protocol Published Link opens in a new window

By BMJ open.

UPDATE TO PRIVACY NOTICE

The personal identifiers, NHS Number and Date of Birth, will be shared with NHS England for the purposes of linkage and extraction of outcomes data, and if the study participant is not happy with this, they can apply to withdraw from the study.

https://www.manchester.ac.uk/discover/privacy-information/data-protection/privacy-notices/

The University of Manchester are the Data Controller for the study (Organisation which alone or with others determines the means of processing the data)

and

The University of Warwick are the Data Processor for the study (Organisation which processes data on behalf of the controller under their instruction (Also referred to as ‘suppliers’ in UK GDPR)).

Professor Dark discusses the lack of evidence surrounding procalcitonin testing for diagnosing and monitoring sepsis and CRP monitoring. He outlines the ADAPT-Sepsis trial, it's relevance in COVID-19 and outcomes.

Key information

Title:

BiomArker-guided Duration of Antibiotic treatment in hospitalised PaTients with suspected Sepsis: the ADAPT-Sepsis Trial

Chief Investigator: Professor Paul Dark

Sponsor: University of Manchester

Funder: Commissioned by NIHR Health Technology Assessment Programme

Registration Number: ISRCTN47473244

Summary:

Sepsis is a common life-threatening condition that is triggered by infection. In sepsis, the body’s defence mechanisms (immune system) react excessively, resulting in widespread inflammation and swelling. If not treated quickly, sepsis can result in shutdown of vital organs which can result in death. Each year in the UK, about 200,000 people develop sepsis and up to a quarter will die. Previous research indicates that early recognition of sepsis and rapid antibiotic treatments are the most important factors for patient survival. While starting antibiotics for sepsis is crucial, the recommended duration of such treatment is uncertain. The lack of research on when to stop treatment safely can lead to an overuse of antibiotics in this condition. Antibiotic overuse is important because it promotes bacteria that are resistant to antibiotics (antimicrobial resistance), which means that sepsis and, indeed, other infections would become difficult to treat in the future. Shorter courses of antibiotics for a patient with sepsis, if given appropriately, may result in less antibiotic use resulting in fewer side effects, less risk of antibiotic resistance and a reduction in costs. Chemicals circulating in the blood can indicate the level of an infection and how effective the treatment of an infection is. These chemicals are called biomarkers. The two most well researched circulating biomarkers in sepsis are C-reactive protein (CRP) and procalcitonin (PCT). They are both protein chemicals produced by the human body in response to infection and can be readily measured in blood samples using NHS laboratory equipment. The aim of this study is to find out whether the duration of antibiotic treatment given to patients with sepsis can be safely reduced following the close daily monitoring of these biomarkers. Patients will have blood samples taken daily whilst receiving antibiotic treatment (typically 7 days), follow-up at 28 & 90 days.

Sample size:

2760 - patients will be randomised across the 3 arms using a ratio of 1:1:1

Primary outcome:

The primary objective of this trial is to determine whether treatment protocols based on monitoring CRP or PCT in hospitalised adult patients with suspected sepsis reduces the duration of antibiotic therapy (superiority) while maintaining treatment safety (non-inferiority) as measured by 28-day mortality.

Duration:

6 years including follow-up

How are students assessed?

Students are required to complete a formative assessment at the end of each block. Students are given the right to sit summative assessments based on completion of formative assessments, engagement with the programme and attendance. Summative assessments are at the end of year one, end of year two and in the final year.

Can I park my car at the Medical School?

Due to the pressures on car parking capacity on campus it is not possible to provide dedicated parking for students. Students can access Pay-and-Display spaces and Pay-on-Foot car parks.Further information about parking on campus.

Can first year students apply for campus accommodation?

Yes, first year students are normally placed in Tocil with other Postgraduate students. There is also off campus Warwick Accommodation available.

 

Let us know you agree to cookies